Business Of Biotech Life Science Connect Editors' Roundtable: Wrapping Up 2025 And Looking Ahead
10 snips
Jan 5, 2026 Guest
Jeff Bugaliskis
Guest
Ray Dogum
Guest
Erin (Aaron) Harris
Guest
Katie Anderson
Guest
Anna Rose Welch
Guest
Ben Comer
Join a dynamic roundtable featuring Ben Comer, Chief Editor at Life Science Leader; Anna Rose Welch, Chief Editor of Advancing RNA; Katie Anderson from Pharmaceutical Online; Erin Harris of Cell and Gene; Ray Dogum from Drug Discovery Online; and Jeff Bugaliskis of Outsource Pharma. They discuss the evolving biotech landscape, from challenges in funding to breakthroughs in cell and gene therapy. Expect insights on mRNA trends, China's growing influence, and the push for AI in manufacturing. Plus, personal highlights and holiday traditions wrap up the conversation!
AI Snips
Chapters
Transcript
Episode notes
Funding Thaw But Early-Stage Pain
- Biotech funding improved slightly in late 2025 but public markets remained sluggish.
- Early-stage drug discovery still faces a hostile funding environment, especially after NIH cuts.
Platform Deals Amid Political Headwinds
- Political and regulatory shifts created uncertainty for mRNA and RNA investments.
- Large platform deals coexisted with investor risk aversion, producing a mixed funding picture.
Outsourcing Resilience To Policy Shocks
- Outsourcing and CDMO sectors showed resilience despite tariffs and policy shocks.
- Some companies shifted production or built US plants to sidestep tariff risks.